Spyre Therapeutics, Inc. · NASDAQ:SYRE
Peter Harwin reported a 9.99% stake in Spyre Therapeutics, Inc. (Schedule 13D/A)
Event Apr 16, 2026 · Filed Apr 20, 2026
Peter Harwin reported a 9.99% stake in Spyre Therapeutics, Inc., 9,016,702 shares, with active intent on Apr 16, 2026. Filed Apr 20, 2026 (Schedule 13D/A).
- Stake
- 9.99%
- Shares
- 9,016,702
- Intent
- Active
- What changed
- Stake changed
- Filed together
- 4 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Fairmount Funds Management LLC | 9.09% | 8,184,941 |
| Fairmount Healthcare Fund II L.P. | 9.09% | 8,184,941 |
| Peter Harwin | 9.99% | 9,016,702 |
| Tomas Kiselak | 9.99% | 9,016,702 |
Source
Related
- Spyre Therapeutics, Inc.
- Harwin Peter Evan
- Spyre Therapeutics, Inc. shareholders
- Schedule 13D/A · Harwin Peter Evan · Oct 9, 2026
- Schedule 13D/A · Harwin Peter Evan · Jun 23, 2026
- Schedule 13D/A · Harwin Peter Evan · Oct 17, 2025
- Form 4 · Burrows Scott L · Oct 2, 2026
- Form 4 · King-Jones Heidy · Oct 2, 2026
- Form 4 · Turtle Cameron · Oct 2, 2026
- Schedule 13G · Paradigm Biocapital Advisors LP · Oct 1, 2026
- Form 4 · King-Jones Heidy · Sep 3, 2026